A spleen-targeting nanoplatform retrains immune cells to fight cancer, transforming 'cold' tumors and significantly reducing postsurgical recurrence in preclinical models.
A spleen-targeting nanoplatform retrains immune cells to fight cancer, transforming 'cold' tumors and significantly reducing postsurgical recurrence in preclinical models.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
A spleen-targeting nanoplatform retrains immune cells to fight cancer, transforming 'cold' tumors and significantly reducing postsurgical recurrence in preclinical models.
Open the app view to save this story, compare related coverage, and continue from the same source.